Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Rosetta Genomics, Clait Health Services Enter mRNA Collaboration

Published: Tuesday, March 25, 2014
Last Updated: Tuesday, March 25, 2014
Bookmark and Share
Partnership with Clalit Health Services' Rabin Medical Center will develop a non-invasive, microRNA-based, assay for the diagnosis of CAD following kidney transplantation.

Under the terms of the agreement, Rosetta will partially fund the research and receive an exclusive worldwide license to the technology, including the right to sublicense the technology. The project is initially planned for a two-year period. Joint patents will be co-owned by Rosetta and Mor, a private corporation incorporated in Israel that is Clalit Health Management Organization's technology transfer company.

Prof. Eytan Mor, Director of the Department of Organ Transplantation, Rabin Medical Center, is the Principal Investigator of the upcoming proof of concept (POC) study to identify a microRNA signature for CAD in blood and/or urine and to assess the feasibility of developing a microRNA-based assay for the non-invasive diagnosis of CAD.

Chronic rejection is currently diagnosed only by histological examination of a tissue sample obtained by biopsy, which is expensive, unpleasant for the patient and unsuitable for serial clinical use due to the risk of bleeding and other complications. Furthermore, morphological changes may be patchy, difficult to interpret and subject to observer bias. Therefore, it is widely accepted that measurement of chronic graft injury is imprecise.

"Despite an improvement in kidney transplant survival in the early post-transplantation stage, there still remains the need for a sensitive, etiology-specific and non-invasive method for monitoring the function of the renal allograft in the late post-transplantation period, where chronic rejection is an almost universal finding," noted Dr.. Alexander Yussim, a leading transplant immunology researcher from Beilinson's transplant department. "The non-invasive test we would like to develop could have potential to enable diagnosis at an earlier stage when this information could alter the choice of therapy and, ultimately, improve outcomes."

"This collaboration provides Rosetta with the opportunity to combine our leading microRNA biomarker technology platform with the expertise of leading organ transplant experts to identify clinically meaningful biomarkers to assess the possibility of developing a non-invasive diagnostic that could provide transplant experts with important information that could help guide their treatment choices to the benefit of their patients," stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. "Following successful results in the POC study, we intend to move forward toward the development and validation of a possible selected microRNA signature. We believe this targeted audience of transplant clinicians can be reached with a small, dedicated commercial team and we aim to launch the product in 2017."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Rosetta Genomics, Rhenium Collaborate
Collaboration aims to distribute RosettaGx Reveal thyroid cancer diagnostic in Israel.
Friday, September 30, 2016
Rosetta Genomics Receives Patent Allowances for MicroRNA-Based Cancer Treatment
Rosetta Genomics receives U.S. patent allowance for microRNA-based ovarian cancer treatment, plus receives two notices of allowance in Israel.
Tuesday, July 12, 2016
Rosetta Genomics Receives Approval from New York State
Company has received approval from the NY State for HEME FISH-based tests for detection of amplifications or rearrangements of DNA in a number of hematologic cancers.
Saturday, June 25, 2016
Rosetta Receives Approval from NY State for Four PCR-Based Assays
BRAF, EGFR, KRAS and NRAS mutation detection assays now available in all 50 states.
Tuesday, May 24, 2016
Rosetta Receives Approval for RosettaGX Reveal™
Company has announced conditional approval status for RosettaGX Reveal™, its novel microRNA classifier for the diagnosis of indeterminate thyroid fine needle aspirate.
Friday, March 04, 2016
Rosetta Receives Approval for Cancer Diagnostic
Conditional approval makes RosettaGX Reveal™ available in all 50 states.
Friday, February 19, 2016
Rosetta Genomics to Acquire PersonalizeDx
Rosetta will gain proprietary tests in prostate, bladder and lung cancer.
Monday, April 13, 2015
Rosetta Genomics Launch Admera’s Sequencing-Based Oncology Tests
The tests will help to predict patient’ responses to drugs based on their personal genetic makeup.
Monday, January 12, 2015
Rosetta Genomics and Moffitt Cancer Center Enter into Strategic Alliance
Leverages strengths of both organizations to develop diagnostic assays for important, unmet needs in cancer.
Friday, September 05, 2014
Rosetta Genomics Expands Management Team
Brings extensive track record in leading commercial teams and driving revenues in microRNA, oncology and thyroid diagnostics.
Tuesday, August 26, 2014
Rosetta Genomics Announces Agreement with Global Pharmaceutical Company
Leverages Rosetta's microRNA biomarker platform and expertise and global pharmaceutical Company's expertise in Alzheimer's biology and drug development to develop a diagnostic for the early detection of Alzheimer's disease.
Tuesday, August 05, 2014
Rosetta Genomics Announces NGS Research Collaboration with Weizmann Institute
Developing novel methods for next-generation sequencing of small RNAs.
Friday, August 01, 2014
Rosetta Genomics Receives Final New York State Approval
Proprietary microRNA diagnostic for identification of four major subtypes of kidney cancer now available in all 50 U.S. states.
Saturday, July 26, 2014
Rosetta Receives Notice of Allowance for U.S. Patent for Ovarian Cancer Treatment
microRNA therapeutic approach complements company's ovarian cancer predictive biomarker work.
Saturday, July 12, 2014
Rosetta Genomics, Moffitt Cancer Center Enter mRNA-Based Cancer Diagnostic Agreement
Partnership to advance the development and commercialization of Rosetta's thyroid neoplasia assay.
Tuesday, June 10, 2014
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Unique Visual Stimulation May Be New Treatment for Alzheimer’s
Noninvasive technique reduces beta amyloid plaques in mouse models of Alzheimer’s disease.
Major Neuroscience Initiative Launched
Tianqiao and Chrissy Chen Institute invest $115 million to further expand neuroscience research, while Caltech construct $200 million biosciences complex.
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Genetics Control Regenerative Properties Of Stem Cells
Researchers define how genetic factors control regenerative properties of blood-forming stem cells.
Diabetes Missing Link Discovered
Researchers from the University of Auckland have shown that beta catenin plays a vital role in the control of insulin release from the pancreas.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!